
Opinion|Videos|December 20, 2023
Enfortumab Vedotin and the Role of ADCs in Bladder Cancer
Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC
4
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
5












